Trevi Therapeutics Inc - Asset Resilience Ratio
Trevi Therapeutics Inc (TRVI) has an Asset Resilience Ratio of 84.84% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Trevi Therapeutics Inc's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Trevi Therapeutics Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Trevi Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see TRVI market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $152.37 Million | 84.84% |
| Total Liquid Assets | $152.37 Million | 84.84% |
Asset Resilience Insights
- Very High Liquidity: Trevi Therapeutics Inc maintains exceptional liquid asset reserves at 84.84% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Trevi Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Trevi Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Trevi Therapeutics Inc (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Trevi Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 87.54% | $169.35 Million | $193.44 Million | +21.25pp |
| 2024-12-31 | 66.30% | $73.53 Million | $110.90 Million | +9.73pp |
| 2023-12-31 | 56.57% | $50.57 Million | $89.40 Million | -31.16pp |
| 2022-12-31 | 87.73% | $107.92 Million | $123.02 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $38.48 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $20.49 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $22.23 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $8.41 Million | -- |
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction i… Read more